.jpg "Michael J. Satlin, MD photo")
Associate Professor
Weill Cornell Medicine
Disclosure(s): AbbVie: DSMB participant; bioMerieux: Grant/Research Support; Merck: Grant/Research Support; Selux Diagnostics: Grant/Research Support; SNIPRBiome: Grant/Research Support
Dr. Michael Satlin an infectious diseases physician and Associate Professor of Medicine and Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. He is the Clinical Director of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell. He completed medical school at the University of Virginia School of Medicine and internal medicine residency and fellowship training at NewYork-Presbyterian Hospital/Weill Cornell. He also obtained a Master’s Degree in Clinical and Translational Investigation at Weill Cornell. His research focuses on the epidemiology, prevention, and treatment of multidrug-resistant Gram-negative infections, with a particular focus on immunocompromised hosts. He has authored or co-authored over 100 peer-reviewed manuscripts. He is a Senior Editor for Journal of Antimicrobial Chemotherapy-Antimicrobial Resistance and serves on Editorial Advisory Boards for Clinical Infectious Diseases, Open Forum Infectious Diseases, and Journal of Clinical Microbiology. He is a Member of the Clinical and Laboratory Standards Institute’s (CLSI) Subcommittee on Antimicrobial Susceptibility Testing and Co-Chair of its Breakpoint Working Group. He is also a Member of the IDSA Guidance Panel for the treatment multidrug-resistant Gram-negatives.